Cipla's Global CEO Subhanu Saxena Resigns; New Replacement Named
Cipla's Global CEO Subhanu Saxena Resigns; New Replacement Named
India, Mumbai, August 12, 2016: Today, Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is pleased to announce the appointment of Umang Vohra as the Managing Director & Global Chief Executive Officer of the Company effective September 1, 2016.
The current incumbent, Subhanu Saxena will step down from his position on August 31, 2016 to attend to emergent family priorities. Subhanu joined Cipla in February 2013 as CEO. Umang joined the company in October 2015 as the Global Chief Financial & Strategy Officer and was elevated as the Global Chief Operating Officer early this year as part of a planned progression. Samina Vaziralli, Executive Director and the Global Head- Strategy, M&A and Cipla New Ventures will be the Executive Vice-Chairman of Cipla effective September 1, 2016. She will move on from her current responsibilities to focus on board and governance issues, in addition to growing Cipla’s strategic priorities through key global partnerships, corporate brand building and public advocacy.
MK Hamied will continue to serve on the Board as the non-executive Vice-Chairman. Commenting on these new appointments, Dr YK Hamied, Non-Executive Chairman, Cipla Ltd said, “Having been aware of his personal circumstances, we respect Subhanu’s decision to leave Cipla. We thank him for his stewardship over the last three years and also for his availability to his successor over the next few months for any transition support. We are delighted to see two young leaders – Umang and Samina – take on higher responsibilities within Cipla. Both have earned their new positions by the dint of the leadership and impact they have already made. Samina’s elevation also reinforces the long-term commitment of the promoter family to Cipla. I am confident that this planned transition will enable Cipla to move into its next orbit of growth while serving true to our mission that None Shall be Denied.”
About Cipla Ltd.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla’s research and development focuses on developing innovative products and drug delivery systems.
Media Contacts:
Corporate Communications
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com
India, Mumbai, August 12, 2016: Today, Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is pleased to announce the appointment of Umang Vohra as the Managing Director & Global Chief Executive Officer of the Company effective September 1, 2016.
The current incumbent, Subhanu Saxena will step down from his position on August 31, 2016 to attend to emergent family priorities. Subhanu joined Cipla in February 2013 as CEO. Umang joined the company in October 2015 as the Global Chief Financial & Strategy Officer and was elevated as the Global Chief Operating Officer early this year as part of a planned progression. Samina Vaziralli, Executive Director and the Global Head- Strategy, M&A and Cipla New Ventures will be the Executive Vice-Chairman of Cipla effective September 1, 2016. She will move on from her current responsibilities to focus on board and governance issues, in addition to growing Cipla’s strategic priorities through key global partnerships, corporate brand building and public advocacy.
MK Hamied will continue to serve on the Board as the non-executive Vice-Chairman. Commenting on these new appointments, Dr YK Hamied, Non-Executive Chairman, Cipla Ltd said, “Having been aware of his personal circumstances, we respect Subhanu’s decision to leave Cipla. We thank him for his stewardship over the last three years and also for his availability to his successor over the next few months for any transition support. We are delighted to see two young leaders – Umang and Samina – take on higher responsibilities within Cipla. Both have earned their new positions by the dint of the leadership and impact they have already made. Samina’s elevation also reinforces the long-term commitment of the promoter family to Cipla. I am confident that this planned transition will enable Cipla to move into its next orbit of growth while serving true to our mission that None Shall be Denied.”
About Cipla Ltd.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla’s research and development focuses on developing innovative products and drug delivery systems.
Media Contacts:
Corporate Communications
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com